Related Experiment Video

Updated: May 31, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

The cyclin-dependent kinase inhibitor AT7519 is a human RORγt agonist

Kaja Karaś1, Joanna Pastwińska1, Anna Sałkowska1

  • 1Laboratory of Epigenetics, Institute of Medical Biology, Polish Academy of Sciences, Łódź, Poland.

Immunology and Cell Biology
|January 24, 2025
PubMed

Insights

AT7519 activates RORγt in immune cells, enhancing anticancer responses. This finding suggests AT7519 could boost cancer immunotherapies like anti-PD-1 and anti-CTLA4 treatments.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • AT7519, a multi-cyclin-dependent kinase inhibitor, has shown anticancer effects.
  • Previous research linked AT7519 to suppressed retinoic acid-related orphan receptor gamma (RORγ) and hepatocellular carcinoma progression.
  • RORγt is an isoform expressed in immune cells crucial for anti-tumor immunity.

Purpose of the Study:

  • To investigate the effect of AT7519 on RORγt, an isoform of RORγ.
  • To determine AT7519's impact on immune cell function within the tumor microenvironment.
  • To explore AT7519's potential as an adjunct therapy in cancer treatment.

Main Methods:

  • Primary human CD4+ T cells were exposed to AT7519 during differentiation.
  • Gene expression analysis was performed to assess the impact of AT7519.
  • Key immune markers including cytokines and checkpoint inhibitors were quantified.

Main Results:

  • AT7519 demonstrated an agonistic effect on RORγt.
  • AT7519 treatment led to increased expression of IL17A/F, IFNG, and GZMB in CD4+ T cells.
  • Expression of PDCD1 (PD-1) and CTLA4 was decreased following AT7519 exposure.

Conclusions:

  • AT7519 exhibits a novel agonistic activity on RORγt, impacting immune cell function.
  • The modulation of immune cell profiles by AT7519 suggests a role in enhancing anti-tumor responses.
  • AT7519 holds potential for integration into cancer immunotherapies, particularly with anti-PD-1 and anti-CTLA4 agents.
Keywords:
AT7519IL17RORγthepatocellular carcinoma

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.8K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.8K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.3K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K